Sign inJoin waitlistJoin the waitlist

Laith Abushahin

Physician · Texas Oncology

Credentials: · · · · · · ·

History

Texas Oncology
2023–Present

Baylor University Medical Center
2011–2013
Internal Medicine
University of Arizona
2008–2009
King Hussein Cancer Center
2007–2008
University of Jordan Faculty of Medicine
2002–2006

Research

Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors
Review · Frontiers in Immunology · 2022 · 291 citations
Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials
Journal of Clinical Medicine · 2020 · 121 citations
Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection
Cancer Medicine · 2020 · 36 citations

TW
Terence Williams
6 papers
Jordan Cloyd
5 papers · 3 as a fellow
Allan Tsung
4 papers
Mary Dillhoff
4 papers
NJ
Ning Jin
4 papers
Adam Wolfe
3 papers · 3 as a resident
Anne Noonan
3 papers
Ashish Manne
3 papers · 2 as a fellow
Aslam Ejaz
3 papers · 2 as a fellow
Timothy Pawlik
3 papers
Bryan Allen
2 papers
John Keech
2 papers

Clinical trials

Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
Principal investigator · Active not recruiting · Phase 2
Anne Noonan
2020–2026
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
Site PI · Recruiting · Phase 3
GlaxoSmithKline
2025–2030